Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review

Frontiers in Pharmacology

Pharmacology

Sean D. Hood¹  Susanne Stanley¹  Bernadette T. Majda²  Lucy Gilkes³  Stephanie Lu⁴  Zahra Cooper⁵  Jennifer Rodger⁶  Bradley Roberts⁶  P. Anthony Akkari⁷  Khan R. L. Collins⁸ 

[1] Division of Psychiatry, School of Medicine, University of Western Australia, Crawley, WA, Australia;School of Medicine, University of Notre Dame, Fremantle, WA, Australia;School of Medicine, University of Notre Dame, Fremantle, WA, Australia;Divison of General Practice, School of Medicine, University of Western Australia, Crawley, WA, Australia;School of Psychological Science, University of Western Australia, Crawley, WA, Australia;The Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia;The Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia;School of Biological Sciences, University of Western Australia, Crawley, WA, Australia;The Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia;School of Human Sciences, University of Western Australia, Crawley, WA, Australia;Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA, Australia;Division of Neurology, Duke University Medical Centre, Duke University, Durham, United States;Western Australian Department of Health, North Metropolitan Health Service, Perth, WA, Australia;

关键词: pharmacogenetics;    pharmacogenomics;    personalised medicine;    cytochrome P450;    drug metabolism;    youth mental health;    depression;    anxiety;   

DOI  :  10.3389/fphar.2023.1267294

 received in 2023-07-26, accepted in 2023-08-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

Pharmacogenetics (PGx) is the study and application of how interindividual differences in our genomes can influence drug responses. By evaluating individuals’ genetic variability in genes related to drug metabolism, PGx testing has the capabilities to individualise primary care and build a safer drug prescription model than the current “one-size-fits-all” approach. In particular, the use of PGx testing in psychiatry has shown promising evidence in improving drug efficacy as well as reducing toxicity and adverse drug reactions. Despite randomised controlled trials demonstrating an evidence base for its use, there are still numerous barriers impeding its implementation. This review paper will discuss the management of mental health conditions with PGx-guided treatment with a strong focus on youth mental illness. PGx testing in clinical practice, the concerns for its implementation in youth psychiatry, and some of the barriers inhibiting its integration in clinical healthcare will also be discussed. Overall, this paper provides a comprehensive review of the current state of knowledge and application for PGx in psychiatry and summarises the capabilities of genetic information to personalising medicine for the treatment of mental ill-health in youth.

【 授权许可】

Unknown   
Copyright © 2023 Roberts, Cooper, Lu, Stanley, Majda, Collins, Gilkes, Rodger, Akkari and Hood.